- Home
- VCSA vs RVPH Comparison
VCSA vs RVPH Comparison
Compare VCSA & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCSA
- RVPH
- Stock Information
- Founded
- VCSA 2009
- RVPH 2006
- Country
- VCSA United States
- RVPH United States
- Employees
- VCSA N/A
- RVPH N/A
- Industry
- VCSA Computer Software: Prepackaged Software
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- VCSA Technology
- RVPH Health Care
- Exchange
- VCSA Nasdaq
- RVPH Nasdaq
- Market Cap
- VCSA 38.6M
- RVPH 33.4M
- IPO Year
- VCSA N/A
- RVPH N/A
- Fundamental
- Price
- VCSA $3.37
- RVPH $1.26
- Analyst Decision
- VCSA Buy
- RVPH Strong Buy
- Analyst Count
- VCSA 4
- RVPH 4
- Target Price
- VCSA $6.08
- RVPH $15.33
- AVG Volume (30 Days)
- VCSA 64.5K
- RVPH 688.9K
- Earning Date
- VCSA 11-07-2024
- RVPH 11-26-2024
- Dividend Yield
- VCSA N/A
- RVPH N/A
- EPS Growth
- VCSA N/A
- RVPH N/A
- EPS
- VCSA N/A
- RVPH N/A
- Revenue
- VCSA $949,936,000.00
- RVPH N/A
- Revenue This Year
- VCSA N/A
- RVPH N/A
- Revenue Next Year
- VCSA N/A
- RVPH N/A
- P/E Ratio
- VCSA N/A
- RVPH N/A
- Revenue Growth
- VCSA N/A
- RVPH N/A
- 52 Week Low
- VCSA $2.07
- RVPH $0.60
- 52 Week High
- VCSA $11.70
- RVPH $5.67
- Technical
- Relative Strength Index (RSI)
- VCSA 59.67
- RVPH 55.87
- Support Level
- VCSA $2.61
- RVPH $0.88
- Resistance Level
- VCSA $3.29
- RVPH $1.22
- Average True Range (ATR)
- VCSA 0.25
- RVPH 0.14
- MACD
- VCSA 0.10
- RVPH 0.02
- Stochastic Oscillator
- VCSA 72.19
- RVPH 64.91
About VCSA Vacasa Inc.
Vacasa Inc is a vacation rental management platform in North America, transforming the vacation rental experience by integrating purpose-built technology with expert local and national teams.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.